TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co said on Thursday half-year profit jumped and the drugmaker would buy back shares it viewed as undervalued.

Takeda Pharmaceutical, Japan’s largest drugmaker by sales, has an appetite for more acquisitions to accelerate overseas growth after saying it would spend about $5 billion to purchase U.S ...

Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management is undertaking an ambitious overhaul to diversify ...

Takeda, Japan's biggest drugmaker, is preparing to make the vaccine domestically and will distribute it in early 2022, pending approval from regulators, the company said in a statement.

Japan's Takeda Pharmaceutical Co said on Wednesday its drug pipeline is poised to drive annual sales up by more than 50%, to 5 trillion yen ($48.01 billion) in the next decade.

TOKYO (AP) — Tsunekazu Takeda, the president of the Japanese Olympic Committee and a powerful IOC member, again denied corruption allegations against him, suggesting on Tuesday that any guilt ...

Over a year into a stunning FDA warning letter, Takeda has resolved manufacturing problems at home as it gears up to make Novavax’s COVID-19 vaccine for Japan. On Oct. 13, the FDA changed the ...

Takeda Pharmaceutical Co (4502.T) said on Tuesday the Japanese government agreed to purchase 150 million doses of the COVID-19 vaccine it will produce using Novavax Inc's formula.